Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montirelin SCHEMBL4955895 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL3098148 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL7354006 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL7311976 | 1.00 | TRHR (0.55) | TRHR | |
| Montirelin SCHEMBL3095581 | 0.99 | TRHR (0.54) | TRHR | |
| Montirelin SCHEMBL8498903 | 0.96 | TRHR (0.52) | TRHR | |
| SCHEMBL7318759 | 0.91 | TRHR (0.54) | TRHR | |
| SCHEMBL14028667 | 0.90 | TRHR (0.43) | TRHR | |
| SCHEMBL7310894 | 0.89 | TRHR (0.52) | TRHR | |
| SCHEMBL8257280 | 0.89 | TRHR (0.42) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4734999-A1 | METHOD OF TREATING DEPRESSION USING SELTOREXANT | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025242852-A1 | SELTOREXANT FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250221992-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-10 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | disclosed |
| US-12201634-B2 | Methods of treating depression using orexin-2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-21 | — | — | US | disclosed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | disclosed |
| EP-4091634-A1 | METHODS OF TREATING DEPRESSION USING OREXIN-2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-115154470-A | Methods of treating depression using orexin-2 receptor antagonists | 詹森药业有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-29 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220105094-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-07 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | TRHR 892/4885 |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | TRHR 833/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | TRHR 107/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | TRHR 892/4885 |
| US-20250221992-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | TRHR 16/4885 |
| US-20220105094-A1 | Methods Of Treating Depression Using Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | TRHR 16/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | TRHR 78/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | TRHR 86/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | TRHR 892/4885 |
| US-12201634-B2 | Methods of treating depression using orexin-2 receptor antagonists | HCRTR2, HCRTR1, CRHR2 | TRHR 16/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | TRHR 232/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | TRHR 61/4885 |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | TRHR 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.